KR20230068378A - 폐암에서 자가항체를 검출하기 위한 항원 조합의 용도 - Google Patents

폐암에서 자가항체를 검출하기 위한 항원 조합의 용도 Download PDF

Info

Publication number
KR20230068378A
KR20230068378A KR1020237004771A KR20237004771A KR20230068378A KR 20230068378 A KR20230068378 A KR 20230068378A KR 1020237004771 A KR1020237004771 A KR 1020237004771A KR 20237004771 A KR20237004771 A KR 20237004771A KR 20230068378 A KR20230068378 A KR 20230068378A
Authority
KR
South Korea
Prior art keywords
ssx1
hud
tumor marker
sox2
koc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237004771A
Other languages
English (en)
Korean (ko)
Inventor
안드레아 머레이
자레드 앨런
필립 거닝
이사벨 맥도널드
셀린 파시-코왈스카
Original Assignee
오엔씨이뮨리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010677754.6A external-priority patent/CN113933509A/zh
Priority claimed from GB2017434.8A external-priority patent/GB2600701A/en
Application filed by 오엔씨이뮨리미티드 filed Critical 오엔씨이뮨리미티드
Publication of KR20230068378A publication Critical patent/KR20230068378A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • G01N33/57423—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G01N33/57484—
    • G01N33/57488—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237004771A 2020-07-14 2021-07-14 폐암에서 자가항체를 검출하기 위한 항원 조합의 용도 Pending KR20230068378A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010677754.6 2020-07-14
CN202010677754.6A CN113933509A (zh) 2020-07-14 2020-07-14 抗体测定
GB2017434.8 2020-11-04
GB2017434.8A GB2600701A (en) 2020-11-04 2020-11-04 Antibody assay
PCT/EP2021/069668 WO2022013321A2 (en) 2020-07-14 2021-07-14 Antibody assay

Publications (1)

Publication Number Publication Date
KR20230068378A true KR20230068378A (ko) 2023-05-17

Family

ID=76971915

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237004771A Pending KR20230068378A (ko) 2020-07-14 2021-07-14 폐암에서 자가항체를 검출하기 위한 항원 조합의 용도

Country Status (6)

Country Link
US (1) US20230266331A1 (https=)
EP (1) EP4182693A2 (https=)
JP (1) JP7744641B2 (https=)
KR (1) KR20230068378A (https=)
CN (1) CN116324412A (https=)
WO (1) WO2022013321A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024197052A1 (en) * 2023-03-20 2024-09-26 Rush University Medical Center Circulating autoantibody biomarkers to supplement lung cancer screening

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
GB2395270B (en) 2002-11-14 2006-08-16 Univ Nottingham Tumour marker proteins and uses thereof
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
US9347945B2 (en) 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
US20100204055A1 (en) * 2008-12-05 2010-08-12 Bonner-Ferraby Phoebe W Autoantibody detection systems and methods
CN103383395B (zh) * 2013-07-10 2015-09-09 杭州市第一人民医院 一种用于检测肺癌自身抗体的液相芯片试剂盒
CN103869086B (zh) 2014-04-14 2016-02-17 杭州凯保罗生物科技有限公司 一种血清自身抗体检测试剂盒
GB201411060D0 (en) 2014-06-20 2014-08-06 Oncimmune Ltd Improved immunoassay method
CN110716050A (zh) 2019-11-13 2020-01-21 基因科技（上海）股份有限公司 抗原组合在制备用于肺癌相关自身抗体检测的试剂盒中的用途以及相应的试剂盒和检测方法

Also Published As

Publication number Publication date
WO2022013321A2 (en) 2022-01-20
JP2023533815A (ja) 2023-08-04
JP7744641B2 (ja) 2025-09-26
CN116324412A (zh) 2023-06-23
EP4182693A2 (en) 2023-05-24
WO2022013321A3 (en) 2022-03-10
US20230266331A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
CN111337678B (zh) 与肿瘤免疫治疗效果相关的生物标志物及其应用
US20110201517A1 (en) Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
US9354233B2 (en) A+ biomarker assays
JP2010509598A (ja) 前立腺癌バイオマーカーを検出するための方法およびキット
CN108107218B (zh) 抗体测定
US20100093108A1 (en) Lung cancer diagnotic assay
US20100216654A1 (en) Biomarkers of prostate cancer and uses thereof
US20090197285A1 (en) Lung Cancer Diagnostic Assay
CN110716050A (zh) 抗原组合在制备用于肺癌相关自身抗体检测的试剂盒中的用途以及相应的试剂盒和检测方法
EP3899541B1 (en) Lung cancer protein epitomic biomarkers
AU2010252907B2 (en) Methods for the diagnosis or prognosis of colorectal cancer
KR20120098992A (ko) 암의 검출을 위한 방법 및 시스템
JP7744641B2 (ja) 肺癌における自己抗体を検出するための抗原の組合せの使用
KR102131860B1 (ko) 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
CN113933509A (zh) 抗体测定
US11193944B2 (en) Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof
GB2600701A (en) Antibody assay
KR102128251B1 (ko) 아르기닌이 메틸화된 drd2에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
TW201928351A (zh) 抗體測定

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902